This report describes atypical absence seizures induced by phenobarbital (PB) in a patient with benign childhood epilepsy with centrotemporal spikes. An 11-year-old girl had nocturnal motor seizures, beginning at the age of 7 years. Interictal EEG displayed centrotemporal sharp waves in the left and right sides alternatively, which increased significantly in frequency during sleep. She was given a diagnosis of benign childhood epilepsy with centrotemporal spike and was treated with valproic acid (VPA), which controlled her seizures for 3 years. She experienced nocturnal Rolandic seizures again, at the age of 10 years 2 months, 10 years 10 months in spite of the regular medication, and PB 60 mg daily was added to the VPA. Her parents noted de novo a few seconds of unresponsive fits 7 days after PB administration. Ictal EEG of the fits revealed diffuse irregular spike and wave bursts (1-4 seconds). VPA and PB in her blood was within the therapeutic ranges. After discontinuing PB, the atypical absence seizures immediately disappeared. Phenobarbital should be added to the list of drugs that potentially provoke de novo seizures.
INTRODUCTION
It is well known that some anticonvulsants may precipitate or exacerbate seizures although the serum concentration will be within the therapeutic range. Most of the reported cases with such adverse reaction were treated with carbamazepine or phenytoin. Phenobarbital (PB) is used widely in the world and has been used for a long time. Some cases have been reported to have involuntary movement induced by PB. Atypical absence seizures induced by PB have not been reported, according to our limited knowledge. This report describes atypical absence seizures provoked by PB in a patient with benign childhood epilepsy with centrotemporal spike (BECTS).
PATIENT REPORT
An 11-year-old girl had nocturnal motor seizures, including hemifacial spasms with drooling or hemiconvulsion, beginning at the age of 7 years. Her past medical history and family history were uneventful, and her developmental milestones were normal. Neurological examination and brain magnetic resonance imaging revealed no abnormality. Interictal EEG displayed centrotemporal sharp waves in the left and right sides alternatively, which increased significantly in frequency during sleep. She was given a diagnosis of BECTS and treated with valproic acid (VPA) 600 mg daily, which controlled her seizures well for 3 years. She experienced Rolandic seizures again, at the age of 10 years 2 months, 10 years 10 months in spite of the regular medication, and PB 60 mg daily was added to the VPA. Her parents noted de novo a few seconds of unresponsive fits 7 days after PB was begun. These fits increased every few minutes in frequency while she was awake, and developed to being accompanied with head nodding or eye blinking one month later. Ictal EEG of the fits revealed diffuse irregular spike and wave bursts (1-4 seconds). Electromyogram of the bilateral trapezius showed no significant change (Figs 1 and 2 ). The alteration of muscle tone of the neck, trunk and extremities was obscure during the fits, for a short duration of the fits, except for the disappearance of artefacts of muscle activities which were superimposed bilaterally on Fp1 of figure. As soon as the spike and wave bursts ended, she could respond quickly to her name. We asked her to try to keep tapping a can with a pen regularly every second for 5 minutes. The rhythm of the tapping was delayed during the fits. The serum concentrations of VPA and PB was 56.0 and 15.6 µg ml −1 , respectively; both of them were within the therapeutic ranges. After the PB was discontinued, the atypical absence seizures immediately disappeared. VPA was increased up to 800 mg daily and then she experienced no seizure for the following 10 months.
DISCUSSION
The rapid appearance of the atypical absences after adding PB, and also their rapid disappearance after discontinuing PB indicate that they were induced by PB; however, a repeat challenge with PB has not been performed. Carbamazepine and phenytoin have been the antiepileptic agents which most commonly induced or aggravated seizures, within or beyond the therapeutic ranges [1] [2] [3] [4] . There have been several reports of PB-induced dyskinesia and interictal epileptic discharges 5 . No report was found that suggested that the seizures were induced or aggravated by using PB, except as an indirect side effect of sleepiness. This is the first report of PB-induced atypical absence seizures in BECTS within the therapeutic range.
Seizures induced or aggravated by antiepileptic drugs should receive more attention. When a patient of BECTS suffers de novo absence seizures, atypical benign partial epilepsy might be diagnosed 6 . How- ever, those seizures may include seizures induced or aggravated by antiepileptic drugs, even by PB. Misdiagnosis may lead to polypharmacy, instead of discontinuing the drug which probably induced the seizures.
The mechanism by which PB produced atypical absence seizures in this patients is not clear. Benzodiazepines (BZDs) have been reported to exacerbate tonic status epilepticus in patients with LennoxGastaut syndrome and to induce microseizures in those with West syndrome [7] [8] [9] . Both BZDs and PB enhance postsynaptic γ -aminobutyric acid (GABA) receptor current by which rapid inhibition is mediated in the central nervous system, to provoke anticonvulsive effects 10, 11 . The duration of PB administration was only a short period in this patient; however, exacerbation of seizures by BZDs was reported in patients with chronic treatment of BZDs [8] [9] [10] . VPA, a concomitant medication in this patient, is thought to have two kinds of antiepileptic properties to intensify the release of GABA and to reduce sustained, high-frequency, repetitive firing of action potentials 10, 11 . The combination of PB and VPA may modulate their effects on each other to induce atypical absence seizures in the patient. Whatever the mechanism is, this report indicates that the combination of PB and VPA in patient with BECTS may provoke de novo seizures.
